Plasticell signs collaboration with UCB
First in kind deal to partner small molecule drugs for stem cell research
‘Using drugs to investigate and direct stem cell differentiation is attracting substantial interest from the pharmaceuticals sector. We are delighted that UCB has chosen us as their partner in this novel program, combining proprietary compound libraries from pharma with our patent-protected, high throughput stem cell screening technology that accelerates discovery research”, commented Dr Yen Choo, CEO of Plasticell.
Plasticell’s unique ability to multiplex experiments will be utilized to test compound libraries in parallel on a broad variety of stem cells, including human embryonic, neural and mesenchymal stem cells. Furthermore, the collaboration will take advantage of Plasticell’s second generation CombiCult™ platform, featuring novel algorithms that assist experimental design and downstream data mining when simultaneously screening hundreds of compounds. All screening will be conducted using serum- and growth factor- free cell culture media, enabling biological function to be more easily elucidated for every hit.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.